Pharmacy Group Journals’ Post

https://lnkd.in/g3wFqQ7p Article Title: A rare case of ciprofloxacin-induced cholestatic hepatits in the newborn Author(s): Mohamed Sellouti*, Karima Laarbi Ouassou, Abdelhakim Ourrai, Amale Hassani, Rachid Abilkassem and Aomar Agadr Journal: Peertechz Journal of Clinical Pharmacology and Clinical Pharmacokinetics Journal ISSN: 2692-4757 Abstract: Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic with wide spectrum of activity against Gram-negative, Gram-positive and anerobic organisms. It has greatest utility in the treatment of children hospitalized with serious bacterial infections. The adverse effects on the liver usually range from asymptomatic elevation of liver enzymes to fulminant hepatitis. #Ciprofloxacin #Cholestasis #Hepatitis #Toxicity #Pharmacy #Pharmacology #PharmaceuticalSciences #ClinicalPharmacy #MedicinalChemistry #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #Pharmacogenomics #Toxicology #Pharmaceutics #Biopharmaceutics #Pharmacognosy #PharmaceuticalChemistry #PharmacyPractice #CommunityPharmacy #HospitalPharmacy #IndustrialPharmacy #RegulatoryAffairs #DrugFormulation #DrugDelivery #PharmacyManagement #PharmaceuticalTechnology #PharmacyEducation #ClinicalTrials

https://lnkd.in/g99k7MQT Article Title: Rheumatoid arthritis: Treatment evolution over the years Author(s): Eleftherios Pelechas1* and Panagiota Karagianni Journal: Peertechz Journal of Clinical Pharmacology and Clinical Pharmacokinetics Journal ISSN: 2692-4757 Introduction Rheumatoid arthritis (RA) is a systemic, inflammatory autoimmune disorder affecting approximately 0.5-1% [1] of the general population. It is characterized by inflammation and proliferation of the synovial lining, leading to destructive changes within the synovial-lined joints [2], especially if left untreated. Patients suffering from RA, usually complain about pain and swelling of the affected joints as well as morning stiffness in and around the joints, lasting at least 1 hour before maximal improvement [3]. #Rheumatoidarthritis #Biologics #Diseasemodifyingantirheumaticdrugs #Personalizedmedicine #Treatmentevolution #Pharmacy #Pharmacology #PharmaceuticalSciences #ClinicalPharmacy #MedicinalChemistry #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #Pharmacogenomics #Toxicology #Pharmaceutics #Biopharmaceutics #Pharmacognosy #PharmaceuticalChemistry #PharmacyPractice #CommunityPharmacy #HospitalPharmacy #IndustrialPharmacy #RegulatoryAffairs #DrugFormulation #DrugDelivery #PharmacyManagement #PharmaceuticalTechnology #PharmacyEducation #ClinicalTrials

https://lnkd.in/gyXyUR2W Article Title: JAK inhibitors: a promising direction for treating Rheumatoid Arthritis Author(s): Pelechas Eleftherios* Journal: International Journal of Pharmaceutical Sciences and Developmental Research Journal ISSN: 2640-7760 Editorial Rheumatoid Arthritis (RA) is a chronic auto inflammatory disease that causes incapacitating changes both the musculoskeletal system and the internal organs [1]. Tumor Necrosis Factor inhibitors (TNFi) promised a new revolutionary era in RA approximately 20 years ago. Since then, different TNFi molecules appeared in that direction. Nowadays, clinicians have also added in their armamentarium the first bio similar in order to combat RA. The main question is: do they have achieved their goal regarding their efficacy, and if yes, at what extent? #Pharmacy #Pharmacology #PharmaceuticalSciences #ClinicalPharmacy #MedicinalChemistry #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #Pharmacogenomics #Toxicology #Pharmaceutics #Biopharmaceutics #Pharmacognosy #PharmaceuticalChemistry #PharmacyPractice #CommunityPharmacy #HospitalPharmacy #IndustrialPharmacy #RegulatoryAffairs #DrugFormulation #DrugDelivery #PharmacyManagement #PharmaceuticalTechnology #PharmacyEducation #ClinicalTrials

Addressing Debilitating or Life-Threatening Diseases, Continuous Manufacturing, and Cutting-Edge Technologies 財團法人醫藥品查驗中心 (Center for Drug Evaluation, CDE) Taiwan has introduced new guidelines to advance the development of innovative therapies for severely debilitating or life-threatening diseases caused by unique genetic variations. These guidelines target various cutting-edge treatments, including antisense oligonucleotide (ASO) drugs, nucleic acid vaccines, and extracellular vesicle preparations. The guidelines aim to ensure safe and effective development, addressing the lack of existing regulations in these areas. Additionally, the adoption of continuous process manufacturing is encouraged to modernize pharmaceutical production, reduce costs, and improve drug quality. For more details please click the link! https://lnkd.in/g-5AjaqF #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-asthma Biologics Phenotyping should consider not only eos & FeNO but also key clinical features: age of disease onset & comorbidities #asthma #phenotyping #biologics #respiratorycare

https://lnkd.in/gpH84aGs Article Title: BAT’s specific Micro-RNA or Novel approach for treatment of obesity: A hypothesis Author(s): Arefhosseini Seyed Rafie*, Farsad Laiegh Amirali, Jazar Hassan and Alijani Sepideh Journal: International Journal of Pharmaceutical Sciences and Developmental Research Journal ISSN: 2640-7760 Abstract Background: Type 2 Diabetes (T2D) is associated with coronary microvascular dysfunction, which is thought to contribute to compromised diastolic function, ultimately culminating in heart failure with preserved ejection fraction (HFpEF). The molecular mechanisms remain incompletely understood, and no early diagnostics are available. We sought to gain insight into biomarkers and potential mechanisms of microvascular dysfunction in obese mice (db/db) and lean rats (Goto-Kakizaki) pre-clinical models of T2D-associated diastolic dysfunction. #Biomarker #Diabetes #Diastolicdysfunction #Endothelialcell #Extracellularvesicle#Heartfailurewithpreservedejectionfraction #Microvasculature #microRNA #Obesity #miRNA22 #BAT #MedicinalChemistry #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #Pharmacogenomics #Toxicology #Pharmaceutics #Biopharmaceutics #Pharmacognosy #PharmaceuticalChemistry #PharmacyPractice #CommunityPharmacy #HospitalPharmacy #IndustrialPharmacy #RegulatoryAffairs #DrugFormulation#DrugDelivery #PharmacyManagement #PharmaceuticalTechnology #PharmacyEducation #ClinicalTrials

Iterum Therapeutics plc Receives FDA Approval of Orlynvah for The Treatment of Uncomplicated Urinary Tract Infections FDA has approved Iterum’s new drug application for Orlynvah (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. This is the first approved indication for Orlynvah and the first FDA-approved product for Iterum. Orlynvah is a novel oral penem antibiotic for the treatment of uUTI. Orlynvah possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins. https://lnkd.in/gHm84Csy #HealthCare #Pharmacy #ClinicalTrials #Antibiotics #UTI #ESBL #Cephalosporins #Orlynvah #Iterum #FDA

https://lnkd.in/gsH5eS6n Article Title: Diabesity Increases Inflammation and Oxidative Stress Author(s): Dayre A, Pouvreau C, Butkowski EG, de Jong B and Jelinek HF* Journal: International Journal of Pharmaceutical Sciences and Developmental Research Journal ISSN: 2640-7760 Abstract Background: Inflammation and oxidative stress are two pathophysiological mechanisms that link obesity, type 2 diabetes mellitus (T2DM) and diabesity. However how levels of inflammatory and oxidative stress markers differ between patients with obesity, T2DM and diabesity has not been completely elucidated. #Diabesity #Inflammation #Oxidativestress #Biomarkers #Pharmacy #Pharmacology #PharmaceuticalSciences #ClinicalPharmacy #MedicinalChemistry #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #Pharmacogenomics #Toxicology #Pharmaceutics #Biopharmaceutics #Pharmacognosy #PharmaceuticalChemistry #PharmacyPractice #CommunityPharmacy #HospitalPharmacy #IndustrialPharmacy #RegulatoryAffairs #DrugFormulation #DrugDelivery #PharmacyManagement #PharmaceuticalTechnology #PharmacyEducation #ClinicalTrials

2024's New FDA Drug Approvals 🌟 Discover the latest from the FDA's CDER: 9 innovative drugs for Q1! 🧴Berdazimer (Zelsuvmi) tackles topical molluscum contagiosum with nitric oxide release. 💉Cefepime/enmetazobactam (Exblifep) combines forces for urinary tract infection relief. 💉LetibotulinumtoxinA (Letybo) smooths glabellar lines with botulinum neurotoxin. 💉Tislelizumab (Tivembra) fights esophageal squamous cell carcinoma with PD-1 mAb technology. 💊Resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, battles nonalcoholic steatohepatitis. 💊Aprocitentan (Tryvio) manages hypertension through endothelin receptor antagonism. 💊Givinostat (Duvyzat) aims at Duchenne muscular dystrophy with HDAC inhibition. 💉Sotatercept (Winrevair), an activin inhibitor, offers hope for pulmonary arterial hypertension patients. 💊Vadadustat (Vafseo) addresses CKD-related anemia in dialysis patients as an oral HIF-PH inhibitor. Explore these groundbreaking treatments! Our appreciation to Chris De Savi for the great compilation! #medicine #pharmaceuticals #drugdevelopment #fda